Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones – Sutro plans to initiate a Phase 2/3 registration-directed study of luvelta for patients with platinum resistant ovarian cancer in the second quarter...
Sutro Biopharma
310 Utah Ave
Suite 150
South San Francisco, CA 94080
650.392.8412
